Portfolio unicorns Oxford Nanopore Technologies and Exscientia g
We are proud to see two of our portfolio unicorn companies achieving significant milestones of successful initial public offerings. As innovative leaders in respective fields, Oxford Nanopore Technologies and Exscientia has revolutionized and led the technological and translational developments in nanopore sequencing and modernizing drug discovery & developments. We look forward to seeing these innovators taking stride in delivering innovation and improving patient care.
More ›